Editorial: Global Obesity Rates Continue to Rise with Challenges for New Drug Treatments Including GLP-1 Receptor Agonists.
This editorial provides a narrative overview of the rapidly escalating global obesity crisis and the evolving landscape of pharmacological treatments, with a focus on GLP-1 receptor agonists such as oral semaglutide. Drawing on the World Obesity Atlas 2025, the authors highlight that the number of adults living with obesity is projected to more than double—from 524 million in 2010 to 1.13 billion by 2030. The editorial notes that the global market for weight-loss medications has been revised upward to $150 billion by 2035, reflecting explosive growth in demand. The authors discuss the FDA's acceptance of a new drug application for oral semaglutide, potentially the first oral agent approved for long-term weight management. Key concerns raised include the limited long-term and real-world safety and efficacy data for GLP-1 receptor agonists, challenges with treatment adherence, and the proliferation of unregulated compounded ("copycat") versions of these drugs that lack quality and safety evaluation. As an editorial, this piece synthesizes publicly available data and regulatory updates rather than presenting original research, and it does not conduct systematic literature searches or meta-analyses. Its conclusions are opinion-based and should be interpreted accordingly.
Why this grade: This is an expert editorial/opinion piece that synthesizes existing data and regulatory developments rather than presenting original clinical trial data, making it a narrative commentary rather than a primary evidence source.
On March 4, 2025, the World Obesity Atlas 2025 was published by the World Obesity Federation and reported that the total number of adults living with obesity is now projected to increase by more than 115% between 2010 and 2030 (from 524 million to 1.13 billion). On May 9, 2025, an analysis of the global market for weight-loss medications identified the exponential growth of obesity drugs, with a previous market projection for 2035 of $105 billion, is now revised to $150 billion. Several emerging oral compounds for weight reduction are currently under clinical evaluation, including oral glucagon-like peptide 1 (GLP-1) receptor agonists. The US Food and Drug Administration (FDA) has recently accepted a new drug application for oral semaglutide, which, if approved, will be the first oral drug authorized for long-term weight management. However, because efficacy and safety data have mainly come from clinical trials, long-term effects on weight loss, treatment adherence, and side effects require long-term and real-world evaluation. Increasing demands and drug costs also drive the production of compounded versions (copycat drugs), which have escalated for GLP-1 receptor agonists, with products without quality and safety evaluation. This editorial aims to provide an update on the global challenges of increasing rates of obesity and the demands for therapeutic approaches to weight loss, including GLP-1 receptor agonists.
Educational summary of published research — not medical advice. License: cc by-nc-nd. Full text is shown only where licensing permits.